Longevity biotech NewLimit raised $435 million in a Series C to fund its first human clinical trial of a cell age reprogramming therapy focused on liver aging. The company’s path to clinic accelerated after a lead liver candidate emerged from its transcription-factor screening platform sooner than earlier timelines. NewLimit packages combinations of transcription factors into lipid nanoparticles in mRNA form to direct cellular “biological age” reset mechanisms in targeted tissues. In preclinical work, the lead candidate increased regenerative capacity in old livers and improved resilience to alcohol-related stress. The funding and near-term planned Phase I initiation underscore a broader shift from platform science to first-in-human translation in cellular reprogramming—an area where the field is waiting for early signals on safety, delivery, and measurable age-related biology.